Legal & General Group’s Audentes Therapeutics, Inc BOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-10,579
| Closed | -$633K | – | 3385 |
|
|
2019
Q4 | $633K | Buy |
10,579
+1,757
| +20% | +$65.9K | ﹤0.01% | 2175 |
|
|
2019
Q3 | $248K | Buy |
8,822
+250
| +3% | +$8.53K | ﹤0.01% | 2309 |
|
|
2019
Q2 | $325K | Buy |
8,572
+1,744
| +26% | +$67K | ﹤0.01% | 2232 |
|
|
2019
Q1 | $267K | Buy |
6,828
+196
| +3% | +$5.62K | ﹤0.01% | 2275 |
|
|
2018
Q4 | $141K | Buy |
6,632
+1,700
| +34% | +$43.9K | ﹤0.01% | 2386 |
|
|
2018
Q3 | $195K | Hold |
4,932
| – | – | ﹤0.01% | 2334 |
|
|
2018
Q2 | $188K | Buy |
4,932
+1,223
| +33% | +$45.3K | ﹤0.01% | 2311 |
|
|
2018
Q1 | $112K | Sell |
3,709
-387
| -9% | -$13.1K | ﹤0.01% | 2454 |
|
|
2017
Q4 | $128K | Sell |
4,096
-612
| -13% | -$16.8K | ﹤0.01% | 2478 |
|
|
2017
Q3 | $134K | Buy |
4,708
+476
| +11% | +$10.3K | ﹤0.01% | 2488 |
|
|
2017
Q2 | $81K | Buy |
4,232
+3,148
| +290% | +$50.3K | ﹤0.01% | 2713 |
|
|
2017
Q1 | $18K | Hold |
1,084
| – | – | ﹤0.01% | 3107 |
|
|
2016
Q4 | $20K | Buy |
+1,084
| New | +$18.7K | ﹤0.01% | 3119 |
|
Legal & General Group's BOLD Position: Q1 2020 in Review
Legal & General Group sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 10,579 shares — an estimated $633K sold.
Legal & General Group first reported a position in BOLD in Q4 2016 and held it in 13 quarters. The position peaked at $633K in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.
- Legal & General Group reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
- Legal & General Group sold 10,579 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $633K.
- Legal & General Group first reported a position in Audentes Therapeutics, Inc in Q4 2016 and held it in 13 quarters.
- Legal & General Group's Audentes Therapeutics, Inc position peaked at $633K in Q4 2019.
- 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.
Based on Legal & General Group's 13F filing for Q1 2020, filed 14 May 2020.